Učitavanje...
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
The programmed death-1 inhibitor pembrolizumab has demonstrated efficacy and safety in clinical trials for treating advanced (unresectable/metastatic) melanoma. We investigated the real-world utilization of pembrolizumab and associated patient outcomes for advanced melanoma in US community oncology...
Spremljeno u:
| Izdano u: | J Immunother |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Lippincott Williams & Wilkins
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5811239/ https://ncbi.nlm.nih.gov/pubmed/29252916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000204 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|